Business Wire

CA-VISA-INC.

11.5.2021 13:02:10 CEST | Business Wire | Press release

Share
Tap to Ride! Monterey-Salinas Transit Becomes 1st in California to Offer Riders the Ability to Tap to Pay with Visa

Today, in collaboration with Visa, Caltrans, Cybersource, Littlepay, and SC Soft, Monterey-Salinas Transit (MST) became the first transit agency in California to offer bus riders a contactless payment option. As cities begin to reopen, public transportation will play a critical role in recovery, and contactless payments can help provide a safe and easy experience for riders and transit operators seeking limited physical touchpoints and interactions. MST riders can now simply tap their contactless credit, debit, prepaid card or payment-enabled device on readers in MST buses for an easy and secure way to travel, without needing to purchase or load a separate transit card or handle cash while boarding.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005504/en/

Visa research shows that enabling tap to pay on transit systems like these can be good for economic recovery, bringing more than a 15% lift in transactions from merchants in surrounding neighborhoods1 . MST is the fifth transit agency in the U.S. to accept tap to pay for fares, following Chicago, Miami, New York and Portland, OR. MST is also the first public transit system in the country that is located outside of a large urban area to introduce tap to pay fares – demonstrating contactless payments as a good fit for any size agency looking to enhance the customer experience.

“Visa recognizes the importance of expanding eligibility and access to fare payment options that meet the needs of a diverse set of transit riders,” said Brian Cole, SVP and head of North America product, Visa. “This effort with MST and Caltrans illustrates how open, contactless payments can support innovative and equitable fare policies to benefit riders and transit operators across the state.”

MST riders who tap will benefit from “fare capping” ensuring riders won’t pay more than $10.00 per day—as long as they pay with the same card or mobile wallet throughout the day. The tap to pay option on MST’s entire bus fleet is the first contactless payment demonstration of the California Integrated Travel Project (Cal-ITP), a Caltrans-led initiative to make travel simpler and more cost-effective for the 40 million California residents, served by 300-plus transit agencies, who collectively take approximately 1.3 billion2 passenger trips annually.

“We are committed to serving all of our riders and delivering new methods of ease and convenience,” said Carl Sedoryk, general manager and CEO, Monterey-Salinas Transit. “The availability of a contactless fare payment system means increased flexibility, and we are thrilled to be collaborating with Visa and Caltrans to bring the enhanced convenience and safety benefits of tap to pay to our community.”

Bringing the MST Demonstration to Life

Cybersource, a Visa solution, Littlepay, a transit-focused payments platform, and SC Soft, a transit ticketing and Automated Fare Collection specialist, have been critical in bringing the MST demonstration to life. Cybersource’s platform is powering the fast-to-market deployment of contactless solutions in the mass transit space, providing a full suite of payment and fraud management tools and an extensive network of partners and acquirers. Cybersource offers brand agnostic transit compliant processing solutions and enables easier implementation of digital payments for operators, while helping protect against fraud. Littlepay provides mass transit transaction processing, including the ability to cap fares and guarantee the best-value fare for frequent riders. SC Soft is a system integrator specializing in ticketing & Automated Fare Collection solutions for transit agencies around the world.

“Cybersource looks forward to supporting Cal-ITP partners to improve transit access within communities throughout the state,” said Fernando Souza, Vice President, Cybersource. “There is a great sense of urgency among transit operators to adopt these solutions and we are committed to powering secure, seamless contactless solutions in a world where no contact, touchless experiences are here to stay.”

“Removing barriers to transit ridership underscores what Cal-ITP is all about, and the launch of this contactless payment demonstration represents a significant step toward a simpler and more equitable public transit system throughout California,” said Caltrans Director Toks Omishakin.

Adoption of contactless payments continues to grow in the U.S. as more consumers realize they can pay for the things they need with a simple and secure tap. In the US, one in 10 face to face Visa transactions are now done with a tap, more than a 2x increase since the beginning of the pandemic, showcasing increased consumer preference for fast, touch-free payment experiences.

About Visa Inc.

Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable, and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device, and a driving force behind the dream of a cashless future for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa , Visa’s Blog and @VisaNews .

__________

1 Visa Q2 FY21 Earnings Transcript
2 Caltrans , FY2018-2019

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye